Room at the Top? The Case for a Chief Value Officer
In the face of growing scrutiny by governments, payers and clinicians, some pharmaceutical organizations are arguably on the back foot when it comes to the price and ‘value’ of treatments. While a degree of hesitancy or strategic uncertainty is understandable, companies may be served better by a more proactive approach. Such is the view espoused in this new Huron paper, which advocates for more coherent stewardship related to three key pillars: value creation, value communication and value governance. Enter the Chief Value Officer with a strategic remit of articulating the value of a company’s products and services as well as the merits of a business model that delivers innovation to patients and others in the healthcare community.
Download the paper below.
Reprint with the permission of In Vivo Pharma IntelligenceDownload Now